At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 108 enrolled
Drug / intervention
etanercept +1 moredrug
Likely dose
etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Apr 2, 2009·Updated Apr 28, 2010
In Brief
A Phase 4 clinical trial evaluating etanercept and etanercept/placebo for Ankylosing Spondylitis. Completed, enrolled 108 participants.
Detailed Summary
The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice therapies in Spain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
Primary CompletionJun 2008
First PostedApr 2009
TodayJul 2026
First PostedApr 2, 2009
Enrollment StartDec 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.3 years ago
Interventions
etanerceptdrug
Etanercept 50 mg twice a week (BIW) for 12 weeks
etanercept/placebodrug
Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks